Form 4: Revolution Medicines' COO Margaret Horn Executes Stock Options and Sells Shares

Margaret Horn, Chief Operating Officer of Revolution Medicines, exercised stock options and sold 50,000 shares of common stock on October 11, 2024, according to a recent SEC filing.

Summary

• On October 11, 2024, Margaret Horn, the Chief Operating Officer of Revolution Medicines, exercised stock options to acquire 50,000 shares of common stock at an exercise price of $4.09 per share.
• Simultaneously, Ms. Horn sold 50,000 shares of Revolution Medicines' common stock at a weighted average price of $50.3411, with individual sales prices ranging from $50.00 to $50.82.
• These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on March 22, 2024.
• Following these transactions, Ms. Horn directly owns 132,320 shares of Revolution Medicines' common stock, which includes 77,300 restricted stock units, and 97,382 stock options.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine disclosure of insider transactions under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares, often under pre-arranged trading plans to avoid accusations of insider trading. The market will likely interpret this as a standard transaction unless the volume is unusually high or accompanied by other news.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include stock options as a significant component.
• The use of 10b5-1 trading plans is a common practice among corporate executives to manage their stock transactions and comply with insider trading regulations.
• Comparable companies like Relay Therapeutics or Black Diamond Therapeutics also see similar filings from their executives.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• Shareholders may see a slight dilution of equity due to the option exercise, but this is offset by the sale of shares back into the market.

Key Dates